TLSA · NASDAQ
Tiziana Life Sciences Ltd
$0.62 -0.01 (-1.59%)
Company overview
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomyosin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $78.9M
- Employees
- 9
- Headquarters
- London
- Website
- tizianalifesciences.com
- CEO
- Ivor R. Elrifi
- Listed
- November 20, 2018
- P/E
- -0.99
- Dividend yield
- 0.00%
Company financials
- Revenue
- $0.00
- Gross profit
- -$421,000
- Operating income
- -$43.4M
- EBITDA
- -$42.3M
- Net income
- -$34.9M
- EPS
- -$0.63
- Total assets
- $11.5M
- Total debt
- $456,000
- Earnings yield
- -101.03%
TLSA
1D
NASDAQ
O0.70H0.71L0.62C0.64-0.05 (-7.55%)Vol420.98K
News